Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies Inc (NQ: TSHA ) 2.070 -0.030 (-1.43%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Taysha Gene Therapies Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus March 31, 2022 Taysha Gene Therapies Inc (NASDAQ: TSHA) is the latest company to slim down by Via Benzinga Recap: Taysha Gene Therapies Q4 Earnings March 31, 2022 Taysha Gene Therapies (NASDAQ:TSHA) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall March 31, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 31, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial January 31, 2022 Taysha Gene Therapies Inc (NASDAQ: TSHA) has Via Benzinga Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial January 27, 2022 Taysha Gene Therapies Inc (NASDAQ: TSHA) reported Via Benzinga Earnings Scheduled For March 31, 2022 March 31, 2022 Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. Via Benzinga Taysha Gene Therapies's Earnings Outlook March 30, 2022 Taysha Gene Therapies (NASDAQ:TSHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict March 30, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome March 29, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Earnings Conference Call Is Coming Up, Here's What You Need To Know March 25, 2022 Taysha Gene Therapies (NASDAQ:TSHA) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results. How to Attend Taysha Gene Therapies (TSHA)... Via Benzinga The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More March 27, 2022 Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. Via Benzinga Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31 March 24, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences March 23, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022 March 09, 2022 Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,... Via Benzinga Two Insider Moonshots Rising on Sudden Buying February 10, 2022 Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future. Via InvestorPlace Stocks That Hit 52-Week Lows On Tuesday March 15, 2022 During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... Via Benzinga Stocks That Hit 52-Week Lows On Monday March 14, 2022 On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by... Via Benzinga Stocks That Hit 52-Week Lows On Tuesday March 08, 2022 Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 March 01, 2022 Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... Via Benzinga Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium February 09, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Tuesday February 22, 2022 During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... Via Benzinga Executives Buy Around $62M Of 3 Stocks February 07, 2022 The Nasdaq index jumped more than 200 points on Friday after Amazon.com, Inc. (NASDAQ: AMZN) reported better-than-expected earnings for its fourth quarter. Via Benzinga Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy January 31, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis January 27, 2022 From Taysha Gene Therapies, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session January 20, 2022 Gainers TCR2 Therapeutics (NASDAQ:TCRR) s... Via Benzinga Stocks That Hit 52-Week Lows On Wednesday January 19, 2022 During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... Via Benzinga Stocks That Hit 52-Week Lows On Thursday January 06, 2022 On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... Via Benzinga Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference January 06, 2022 From Taysha Gene Therapies, Inc. Via Business Wire Stocks Hitting New 52-Week Lows Today January 03, 2022 On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.